Unavailability of the Investigator Nedostupnost zkoušejícího Sample Clauses

Unavailability of the Investigator Nedostupnost zkoušejícího. 6.2.1 The Investigator is essential to the Study being conducted under this Agreement. Whereas the Investigator shall oversee the entire Study, in his or her temporary absence the Investigator shall designate these responsibilities to a qualified sub- investigator, who shall be identified in writing. When the Investigator’s absence is anticipated to exceed seven (7) days, CRO shall be notified in writing of the designated sub-investigator who shall assume the Study responsibilities. CRO and/or Sponsor may approve or reject Přítomnost Zkoušejícího xx xxxxxxx pro provádění Klinického hodnocení dle této Smlouvy. Vzhledem k tomu, že Zkoušející bude dohlížet na průběh celého Klinického hodnocení, pak v případě dočasné nepřítomnosti Zkoušejícího Zkoušející deleguje tuto odpovědnost na svého kvalifikovaného spolupracovníka, který bude určen písemně. V případě, kdy se předpokládá, že nepřítomnost Zkoušejícího přesáhne sedm (7) dní, bude CRO informována písemně any proposed sub-investigator. Such approval shall not be unreasonably withheld. Should a permanent substitution for the Investigator be required, the Institution shall notify CRO and Sponsor in writing, in accordance with Section 15.3. The Institution may not permanently substitute other investigators, or make substantial changes in the level of effort asserted by the Investigator, without the prior written approval of CRO in the absence of which CRO shall be entitled to invoke the provisions of Section 11.3.1.6 below. o navrženém spolupracovníkovi Zkoušejícího, který převezme odpovědnost související s Klinickým hodnocením. CRO může svým jménem nebo jménem Zadavatele schválit nebo odmítnout jakéhokoliv navrženého spolupracovníka Zkoušejícího. Schválení nebude odepřeno bezdůvodně. Pokud bude požadována stálá náhrada Zkoušejícího, bude Zdravotnické zařízení informovat CRO písemně v souladu s článkem 15.
Sample 1See All (17)
AutoNDA by SimpleDocs
Unavailability of the Investigator Nedostupnost zkoušejícího. 6.2.1 The Investigator is essential to the Study being conducted under this Agreement. Whereas the Investigator shall oversee the entire Study, in his or her temporary absence the Health Service Provider/Investigator shall designate these responsibilities to a qualified sub-investigator, who shall be identified in writing. When the Investigator’s absence is anticipated to exceed seven (7) days, ICON shall be notified in writing of the designated sub-investigator who shall assume the Study responsibilities. ICON on its own behalf or that of the Sponsor may approve or reject any proposed sub-investigator. Such approval shall not be unreasonably withheld. Should a permanent substitution for the Investigator be required, the Health Service Provider shall notify ICON in writing, in accordance with Section 15.3. The Health Service Provider may not permanently substitute other investigators, or make substantial changes in the level of effort asserted by the Investigator, without the prior written approval of ICON in the absence of which ICON shall be entitled to invoke the provisions of Section 11.3.1.6 below. Zkoušející je pro provedení studie dle této smlouvy zcela nezbytný. Jelikož bude zkoušející dohlížet nad celým průběhem studie, musí v jeho nepřítomnosti poskytovatel zdravotních služeb / zkoušející přidělit tyto povinnosti způsobilému spoluzkoušejícímu, který bude určen písemně. Má-li předpokládaná absence zkoušejícího překročit sedm (7) dnů, musí být společnost ICON písemně informována o jmenovaném spoluzkoušejícím, který převezme povinnosti vyplývající ze studie. Společnost ICON může svým vlastním jménem nebo jménem zadavatele jakéhokoli navrhovaného spoluzkoušejícího schválit nebo odmítnout. Takové schválení nebude bezdůvodně odpíráno. Bude-li nutné zkoušejícího nahradit trvale, poskytovatel zdravotních služeb společnost ICON písemně uvědomí v souladu s článkem 15.3. Poskytovatel zdravotních služeb nesmí trvale nahradit jiné zkoušející ani provádět podstatné změny v úrovni činnosti zkoušejícího bez předchozího písemného souhlasu společnosti ICON. V případě neexistence takového souhlasu má společnost ICON právo uplatnit ustanovení článku 11.3.1.6 níže. 7.1 Receipt of the Investigational Product Převzetí hodnoceného přípravku 7.1.1 The Investigator shall verify receipt of the Investigational Product by signing the appropriate document(s)/form(s) provided by the Sponsor, ICON or a supplier designated by the Sponsor or ICON Zkoušející potvrdí převzetí hodno...
Sample 1
Unavailability of the Investigator Nedostupnost zkoušejícího. The Investigator is essential to the Study being conducted under this Agreement. Whereas the Institution shall ensure that the Investigator shall oversee the entire Study, in his or her temporary absence the Přítomnost zkoušejícího je pro provádění klinického hodnocení podle této smlouvy zásadní. Vzhledem k tomu, že zdravotnické zařízení zajistí, že zkoušející bude dohlížet na průběh celého klinického hodnocení, v případě jeho dočasné nepřítomnosti 3.17
Sample 1
Unavailability of the Investigator Nedostupnost zkoušejícího. 6.2.1 The Investigator is essential to the Study being conducted under this Agreement. Whereas the Investigator shall oversee the entire Study, in his or her temporary Přítomnost Zkoušejícího je zásadní pro provádění Klinického hodnocení dle této Smlouvy. Vzhledem k tomu, že Zkoušející bude dohlížet na prnběh absence the Institution/Investigator shall designate these responsibilities to a qualified sub-investigator, who shall be identified in writing. When the Investigator’s absence is anticipated to exceed seven (7) days, CRO shall be notified in writing of the designated sub-investigator who shall assume the Study responsibilities. CRO and/or Sponsor may approve or reject any proposed sub-investigator. Such approval shall not be unreasonably withheld. Should a permanent substitution for the Investigator be required, the Institution shall notify CRO and Sponsor in writing, in accordance with Section 15.3. The Institution may not permanently substitute other investigators, or make substantial changes in the level of effort asserted by the Investigator, without the prior written approval of CRO in the absence of which CRO shall be entitled to invoke the provisions of Section 11.3.1.6 below.
Sample 1
Unavailability of the Investigator Nedostupnost zkoušejícího. The Investigator is essential to the Study being conducted under this Přítomnost zkoušejícího je pro provádění klinického hodnocení podle této smlouvy
Sample 1
Unavailability of the Investigator Nedostupnost zkoušejícího. The Investigator is essential to the Study being conducted under this Agreement. Whereas the Institution shall ensure that the Investigator shall oversee the entire Study, in his or her temporary absence the Institution shall designate these responsibilities to a qualified sub-investigator, who shall be identified in writing. When the Investigator’s absence is anticipated to exceed seven (7) days, ICON shall be notified in writing of the designated sub-investigator who shall assume the Study responsibilities. ICON on its own behalf or that of the Sponsor may approve or reject any proposed sub-investigator. Such approval shall not be unreasonably withheld. Should a permanent substitution for the Investigator be required, the Institution shall notify ICON in writing, in accordance with Section 12.3. The Institution may not permanently substitute other investigators, or make substantial changes in the level of effort asserted by the Investigator, without the prior written approval of ICON in the absence of which ICON shall be entitled to invoke the termination provisions of Section 8.3.1.6
Sample 1

Related to Unavailability of the Investigator Nedostupnost zkoušejícího

  • DEVELOPMENT OR ASSISTANCE IN DEVELOPMENT OF SPECIFICATIONS REQUIREMENTS/ STATEMENTS OF WORK

  • Corporate Examinations and Investigations Prior to the Closing Date, the parties acknowledge that they have been entitled, through their employees and representatives, to make such investigation of the assets, properties, business and operations, books, records and financial condition of the other as they each may reasonably require. No investigations, by a party hereto shall, however, diminish or waive any of the representations, warranties, covenants or agreements of the party under this Agreement.

  • Vlastnictví Zdravotnické zařízení si ponechá a bude uchovávat Zdravotní záznamy. Zdravotnické zařízení a Zkoušející převedou na Zadavatele veškerá svá práva, nároky a tituly, včetně práv duševního vlastnictví k Důvěrným informacím (ve smyslu níže uvedeném) a k jakýmkoli jiným Studijním datům a údajům.

  • Search, Enquiry, Investigation, Examination And Verification a. The Property is sold on an “as is where is basis” subject to all the necessary inspection, search (including but not limited to the status of title), enquiry (including but not limited to the terms of consent to transfer and/or assignment and outstanding charges), investigation, examination and verification of which the Purchaser is already advised to conduct prior to the auction and which the Purchaser warrants to the Assignee has been conducted by the Purchaser’s independent legal advisors at the time of execution of the Memorandum. b. The intending bidder or the Purchaser is responsible at own costs and expenses to make and shall be deemed to have carried out own search, enquiry, investigation, examination and verification on all liabilities and encumbrances affecting the Property, the title particulars as well as the accuracy and correctness of the particulars and information provided. c. The Purchaser shall be deemed to purchase the Property in all respects subject thereto and shall also be deemed to have full knowledge of the state and condition of the Property regardless of whether or not the said search, enquiry, investigation, examination and verification have been conducted. d. The Purchaser shall be deemed to have read, understood and accepted these Conditions of Sale prior to the auction and to have knowledge of all matters which would have been disclosed thereby and the Purchaser expressly warrants to the Assignee that the Purchaser has sought independent legal advice on all matters pertaining to this sale and has been advised by his/her/its independent legal advisor of the effect of all the Conditions of Sale. e. Neither the Assignee nor the Auctioneer shall be required or bound to inform the Purchaser of any such matters whether known to them or not and the Purchaser shall raise no enquiry, requisition or objection thereon or thereto.

  • Outpatient Dental Anesthesia Services This plan covers anesthesia services received in connection with a dental service when provided in a hospital or freestanding ambulatory surgical center and: • the use of this is medically necessary; and • the setting in which the service is received is determined to be appropriate. This plan also covers facility fees associated with these services. This plan covers dental care for members until the last day of the month in which they turn nineteen (19). This plan covers services only if they meet all of the following requirements: • listed as a covered dental care service in this section. The fact that a provider has prescribed or recommended a service, or that it is the only available treatment for an illness or injury does not mean it is a covered dental care service under this plan. • dentally necessary, consistent with our dental policies and related guidelines at the time the services are provided. • not listed in Exclusions section. • received while a member is enrolled in the plan. • consistent with applicable state or federal law. • services are provided by a network provider.

  • SERVICE MONITORING, ANALYSES AND ORACLE SOFTWARE 11.1 We continuously monitor the Services to facilitate Oracle’s operation of the Services; to help resolve Your service requests; to detect and address threats to the functionality, security, integrity, and availability of the Services as well as any content, data, or applications in the Services; and to detect and address illegal acts or violations of the Acceptable Use Policy. Oracle monitoring tools do not collect or store any of Your Content residing in the Services, except as needed for such purposes. Oracle does not monitor, and does not address issues with, non-Oracle software provided by You or any of Your Users that is stored in, or run on or through, the Services. Information collected by Oracle monitoring tools (excluding Your Content) may also be used to assist in managing Oracle’s product and service portfolio, to help Oracle address deficiencies in its product and service offerings, and for license management purposes. 11.2 We may (i) compile statistical and other information related to the performance, operation and use of the Services, and (ii) use data from the Services in aggregated form for security and operations management, to create statistical analyses, and for research and development purposes (clauses i and ii are collectively referred to as “Service Analyses”). We may make Service Analyses publicly available; however, Service Analyses will not incorporate Your Content, Personal Data or Confidential Information in a form that could serve to identify You or any individual. We retain all intellectual property rights in Service Analyses. 11.3 We may provide You with the ability to obtain certain Oracle Software (as defined below) for use with the Services. If we provide Oracle Software to You and do not specify separate terms for such software, then such Oracle Software is provided as part of the Services and You have the non-exclusive, worldwide, limited right to use such Oracle Software, subject to the terms of this Agreement and Your order (except for separately licensed elements of the Oracle Software, which separately licensed elements are governed by the applicable separate terms), solely to facilitate Your use of the Services. You may allow Your Users to use the Oracle Software for this purpose, and You are responsible for their compliance with the license terms. Your right to use any Oracle Software will terminate upon the earlier of our notice (by web posting or otherwise) or the end of the Services associated with the Oracle Software. Notwithstanding the foregoing, if Oracle Software is licensed to You under separate terms, then Your use of such software is governed by the separate terms. Your right to use any part of the Oracle Software that is licensed under the separate terms is not restricted in any way by this Agreement.

  • Technical Feasibility of String While ICANN has encouraged and will continue to encourage universal acceptance of all top-­‐level domain strings across the Internet, certain top-­‐level domain strings may encounter difficulty in acceptance by ISPs and webhosters and/or validation by web applications. Registry Operator shall be responsible for ensuring to its satisfaction the technical feasibility of the TLD string prior to entering into this Agreement.

  • Elements Unsatisfactory Needs Improvement Proficient Exemplary IV-A-1. Reflective Practice Demonstrates limited reflection on practice and/or use of insights gained to improve practice. May reflect on the effectiveness of lessons/ units and interactions with students but not with colleagues and/or rarely uses insights to improve practice. Regularly reflects on the effectiveness of lessons, units, and interactions with students, both individually and with colleagues, and uses insights gained to improve practice and student learning. Regularly reflects on the effectiveness of lessons, units, and interactions with students, both individually and with colleagues; and uses and shares with colleagues, insights gained to improve practice and student learning. Is able to model this element.

  • Liability of the Evaluator The Trustee, the Depositor and the Unit holders may rely on any Evaluation furnished by First Trust Advisors L.P., acting in its capacity as Evaluator, and shall have no responsibility for the accuracy thereof. The determinations made by the Evaluator hereunder shall be made in good faith upon the basis of the best information available to it. The Evaluator shall be under no liability to the Trustee, the Depositor or the Unit holders for errors in judgment; provided, however, that this provision shall not protect the Evaluator against any liability to which it would otherwise be subject by reason of willful misfeasance, bad faith or gross negligence in the performance of its duties or by reason of its reckless disregard of its obligations and duties hereunder.

  • Information Systems Acquisition Development and Maintenance a. Client Data – Client Data will only be used by State Street for the purposes specified in this Agreement.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!